RedChip Companies

RedChip is the world leader in investor relations, financial media, and research for microcap and small-cap stocks. RedChip has helped hundreds of companies achieve their capital markets goals and has been ranked by Inc. Magazine as one of the fastest growing privately held investor relations firms in the U.S. #finance #capitalmarkets #investorrelations

📢 VENU Holding Corp. (NYSE American: VENU) Investor Webinar Today at 4:15 PM EST – Discover the Future of Live Entertainment VENU is inviting investors to a special webinar today at 4:15 PM EST. Don’t miss this deep dive into one of the most innovative models in the entertainment industry. 🎯 Why Investors Should Tune In: 💰 $77.7M in FireSuite sales for 2024, with $200M projected for 2025 🏟️ 11 new venues in development, targeting $1.5B+ in annual ticket receipts 🏆 Ford Amphitheater’s first season: 96,000 fans and $12.7M in revenue 🤝 Strategic alliances with AEG Presents, Ford Motor Company, Budweiser, The Coca-Cola Company, and NFL legend Troy Aikman VENU blends luxury real estate, public-private partnerships, and premium entertainment for scalable, high-margin growth—while maintaining a low-risk financial profile. 🔗 https://lnkd.in/d3RHCFrf VenuesNow Real Estate #RedChip #RedChat #VENU #LiveEntertainment #RevenueGrowth #Investing #SmallCapStocks #Hospitality

🧪 Enlivex Therapeutics (Nasdaq: ENLV) Phase II Knee Osteoarthritis Trial Fully Enrolled — Key Milestone Reached Following promising Phase I efficacy signals, Enlivex has completed patient enrollment in the Phase II stage of its Phase I/II trial evaluating Allocetra™ for moderate to severe knee osteoarthritis (OA) — totaling 133 patients. 📊 Why This Matters to Investors: - Progress Toward Data Readout: 3-month topline results expected by August 2025. - Large Unmet Market: Knee OA impacts over 32.5M Americans—with no FDA-approved treatments proven to reverse structural joint damage. - Differentiated Approach: Allocetra™, a macrophage reprogramming therapy, targets immune system rebalancing to address chronic inflammation at its root. 🎯 A positive Phase II readout could position Enlivex Therapeutics (Nasdaq: ENLV) for significant upside in a multi-billion-dollar market. 🔗 https://lnkd.in/e72XQQEB Biotechnology Biotechnology News Arthritis #RedChip #RedChat #ENLV #BiotechStocks #Osteoarthritis #ClinicalTrials #HealthcareInnovation #Investing

Venu Holding Corporation (NYSE American: VENU) Showcasing Growth at Mar-a-Lago Investor Event VENU is taking center stage at President Trump’s Mar-a-Lago on April 22, 2025, where CEO JW Roth will present the company’s upscale live entertainment and hospitality strategy to top investors. 📊 Key Highlights: - 114% YoY Asset Growth: Total assets surged to ~$95M at year-end 2024. - Explosive Sales Momentum: Luxe FireSuite fractional ownership sales hit $10.4M in Jan, $11.2M in Feb, and $17.1M in Mar — on track for $200M in 2025. - Expanding Footprint: New multi-season amphitheaters in Texas and Oklahoma will host up to 20,000 guests. 💡 Why This Matters: VENU is scaling a high-demand, premium experience model with strong revenue traction and national recognition — including features in The Wall Street Journal, The New York Times, and  Variety. 📄 https://lnkd.in/esRgp87j Troy Aikman EIGHT Elite Light Lager AEG VenuesNow #RedChip #RedChat #VENU #LiveEntertainment #RevenueGrowth #Investing #SmallCapStocks #Hospitality

Nexalin Technology (Nasdaq: NXL): Supporting Medicare Reimbursement for AI-Enabled Devices Nexalin Technology has voiced strong support for the bipartisan Health Tech Investment Act (S.1399), which could accelerate Medicare reimbursement for FDA-cleared AI-integrated medical devices — a move that aligns directly with the company’s upcoming Gen-3 HALO Clarity™ system. 🧠 Why This Matters to Investors: ✅ Strategic Fit: Nexalin's Gen-3 HALO Clarity™ integrates AI into neurostimulation for anxiety, depression & insomnia — supported by a virtual clinic platform. ✅ Policy Tailwind: The proposed bill would assign transitional Medicare payment codes for up to 5 years, closing the gap between FDA approval and CMS reimbursement. ✅ Market Advantage: This legislation could fast-track adoption of Nexalin Technology's AI-powered device in U.S. healthcare — especially in underserved mental health markets. 📄 Read the Full Announcement: https://lnkd.in/e75bprac Mental Health America Neurostimulation Genetic Engineering & Biotechnology News #Nexalin #RedChip #RedChat #Biotech #MentalHealth #PTSD #DefenseTech #Investing

📢 Greenwich LifeSciences (Nasdaq: GLSI) to Host Investor Webinar on Advancing Breast Cancer Immunotherapy Greenwich LifeSciences, Inc. invites investors to a live webinar on Tuesday, April 29 at 4:15 PM EST to discuss the ongoing development of GLSI-100, an immunotherapy designed to reduce breast cancer recurrence in HER2/neu-positive patients. 💡 Why Investors Should Tune In: 🔬 Promising Phase IIb Results: Over 80% reduction in recurrence among HER2 3+ patients after 5 years of follow-up, with no serious adverse events reported. 🧪 Phase III Trial in Progress: The global FLAMINGO-01 study spans 150 clinical sites across the U.S. and Europe in collaboration with leading oncology research networks. 📊 Significant Market Opportunity: HER2-positive breast cancer affects hundreds of thousands of patients annually in the U.S. and EU. GLSI-100 targets patients who may not fully benefit from existing therapies like Herceptin or Kadcyla. 🎯 Gain insights into Greenwich LifeSciences, Inc.'s clinical strategy and upcoming milestones. 🔗 https://lnkd.in/efUguQhq Biotechnology Biotechnology News Breast Cancer Now #GLSI #BreastCancer #BiotechStocks #ClinicalTrials #HER2 #Immunotherapy #InvestorWebinar #OncologyInvesting 

🚀 bioAffinity Technologies (Nasdaq: BIAF): Major Efficiency Gains for CyPath Lung Test! bioAffinity Technologies has significantly enhanced the efficiency of its CyPath® Lung diagnostic, a noninvasive test for early lung cancer detection. Key updates include: ✅ 50% Faster Data Acquisition ✅ 60% Lower Sample Processing Costs ✅ 25%+ Decrease in Per-Test Cost ✅ No Changes to Patient Experience or Test Accuracy (92% sensitivity, 87% specificity) 🧪 These improvements boost lab throughput by over 10%, reduce reagent use, and preserve test performance—strengthening CyPath Lung’s position as a cost-effective and scalable solution in the fight against lung cancer. 💰 A recent economic study showed potential U.S. healthcare savings of up to $1.27 billion annually if CyPath® Lung were integrated into standard care. 📄 https://lnkd.in/eA9CK8hV Titus Regional Medical Center Pulmonology Precision Pathology Laboratory Services U.S. Department of Veterans Affairs Breast Cancer Now #BiotechStocks #LungCancer #EarlyDetection #HealthcareInnovation #Investing

💰 Better Choice Company (NYSE:BTTR) Reinstates and Expands Stock Repurchase Program to $6.5M Better Choice is doubling down on shareholder value—its Board has reinstated the company’s buyback program and increased authorization to $6.5M through the end of 2025. 📈 Under the prior $5M program, Better Choice Company (NYSE:BTTR) repurchased 102,405 shares at an average price of $1.99. The move signals confidence in the company’s valuation and long-term prospects. 🔍 Why This Matters for Investors: • Undervalued Signal: Leadership sees current share price as below intrinsic value. • Flexible Capital Deployment: Repurchases to be funded from cash on hand. • Shareholder-Focused Strategy: Potential to enhance EPS and reduce share float. 📄 https://lnkd.in/ekwfCyBG ▼Pet Food Processing Veterinary Practice Biotechnology News #BTTR #ShareBuyback #StockRepurchase #PetWellness #InvestorUpdate #FinancialNews #EquityValue

🧬 Calidi Biotherapeutics (NYSE American: CLDI): FDA Greenlights IND for Novel Solid Tumor Therapy Calidi Biotherapeutics has received FDA clearance for its Investigational New Drug (IND) application for CLD-201—a first-in-class, allogeneic stem cell-based immunotherapy targeting solid tumors, including breast cancer, head & neck cancer, and soft tissue sarcoma. 💡 Why This Matters to Investors: - Clinical Advancement: This IND paves the way for first-in-human trials, marking a key milestone in Calidi Biotherapeutics' oncology pipeline. - Innovative Tech: CLD-201 combines stem cells with oncolytic vaccinia virus to evade immune inactivation and directly kill cancer cells. - Market Opportunity: Addresses major unmet needs in cancers with limited effective treatment options. 📄 https://lnkd.in/eTZEgsbf California Institute for Regenerative Medicine (CIRM) Northwestern University City of Hope The Lancet Group #BiotechStocks #CancerTreatment #SolidTumors #FDAApproval #ClinicalTrials #Immunotherapy #InvestorNews

💸 ConnectM Technology Solutions (Nasdaq: CNTM): Aggressive Debt Reduction Sharpens Financial Trajectory ConnectM Technology Solutions has retired another $9M in debt in April—bringing total debt eliminated since going public in July 2024 to $40M. Outstanding liabilities now sit under $8M, and the company expects to achieve positive stockholder equity by Q2 2025. 📈 Why This Matters to Investors: - 90% Reduction in annual interest expense enhances profitability outlook. - Strengthened balance sheet positions ConnectM Technology Solutions for strategic growth in the clean energy and tech space. - Financial flexibility could support future acquisitions, R&D, or expansion into new markets. 🔗 https://lnkd.in/ecUkGbPq GE Vernova's Electrification businesses Electrification Institute S&P Global Commodity Insights #CNTM #SmallCapStocks #DebtReduction #CleanTech #EnergyInnovation #Investing #FinancialNews #BalanceSheetStrength